PubMed · 2000 · 371 citations · 32 references
Life SciencesNeurologyNeuroscienceClinical NeuroscienceNeurodegenerationNeuropathologyAmyotrophic Lateral SclerosisMotor Neuron DiseasesNeurodegenerative DiseasesNeurodegenerative DisordersAmyotrophic Lateral Sclerosis PathologyBulbar Onset Amyotrophic Lateral SclerosisBulbar Onset DiseaseBulbar Symptoms
BACKGROUND: The El Escorial and the revised Airlie House diagnostic criteria for amyotrophic lateral sclerosis (ALS) classify patients into categories reflecting different levels of diagnostic certainty. We conducted a prospective, population-based study of the natural course of ALS in the Republic of Ireland during a 6-year period to examine the utility of these ALS diagnostic criteria. METHODS: Using data from the Irish ALS Register, we studied the clinical features of all patients diagnosed as having ALS in Ireland throughout their illness. RESULTS: Between 1993 and 1998, 388 patients were diagnosed as having ALS. Forty percent of patients reported bulbar-onset symptoms. Disease progression occurred over time: at last follow-up, 75% of all patients had bulbar signs, compared with 59% at diagnosis. When the El Escorial criteria were applied, more than half of patients (218 [56%]) had definite or probable ALS at diagnosis. Of the 165 possible and suspected ALS cases at diagnosis (trial ineligible), 110 (67%) were trial eligible at last follow-up. Of the 254 patients who had died, 229 (90%) had definite or probable ALS, whereas 25 patients (10%) remained trial ineligible at death. El Escorial category at diagnosis was not a significant prognostic indicator. Use of the Airlie House criteria had no effect on the median time from symptom onset to trial eligibility (12.9 vs 12.8 months). CONCLUSIONS: The El Escorial and Airlie House diagnostic criteria are excessively restrictive. Furthermore, levels of diagnostic certainty cannot be used as prognostic indicators. Arch Neurol. 2000;57:1171-1176
32
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Lucette Lacomblez, Gilbert Bensimon, Vincent Meininger et al. · The Lancet · 1996 · 1.3K citations